How has this simple tool helped to shape drug discovery over the years?

Jazz Pharmaceuticals is set to initiate a single-arm, pivotal Phase II/III study of JZP-458 as a potential treatment option for acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LBL) patients.

The company previously reported positive results from the Phase I study of the recombinant crisantaspase molecule, JZP-458. The study met its efficacy and safety objectives.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The study was conducted in healthy volunteers in the US, with the efficacy being based on the measurement of serum asparaginase activity levels.

Jazz Pharmaceuticals Research and Development executive vice-president Robert Iannone said: “Jazz is committed to the ALL patient community, and we are pleased to advance this development programme with the goal of bringing a new treatment option to ALL and LBL patients who are hypersensitive to E. coli-derived asparaginase products as soon as possible.

“Following a meeting with the US Food and Drug Administration, we are finalising the Phase II/III study protocol in collaboration with the Children’s Oncology Group and plan to initiate the study later this year.”

JZP-458 uses a novel Pseudomonas fluorescens expression platform and is being developed for use as a component of a multi-agent chemotherapeutic regimen to treat pediatric and adult patients with ALL or LBL.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

ALL is a cancer of the blood and bone marrow that can progress quickly if left untreated.

According to the American Cancer Society estimations, almost 6,000 new cases of ALL will be diagnosed in the US this year.

Last November, Jazz Pharmaceuticals enrolled the first patient in a Phase III clinical trial to assess the efficacy and safety of JZP-258 to treat idiopathic hypersomnia.

The double-blind, placebo-controlled, randomised-withdrawal trial aims to enrol around 140 adult patients.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact